This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
== Principle == This technique is applicable to gases or any materials that can be vaporized. It uses a non-fragmenting non-conventional ionisation mode, by attachment of a lithium (or alkaline) ion to the gas to be analysed with a more traditional mass filter. This instrument is more dedicated to analysis of moderately-sized molecules such as organic or aromatic compounds.
The Vietnam War descended into a quagmire for the United States, leading to a decline in international prestige and economic stability, derailing arms agreements, and provoking domestic unrest. America's withdrawal from the war led it to embrace a policy of détente with both China and the Soviet Union.
==== Increasing Bystander Intervention ==== There are currently two types of laws in place to reduce opioid overdoses through increased bystander intervention: Good Samaritan Laws (GSLs) and Naloxone Access Laws (NALs). GSLs allow a bystander to not face civil damages when acting in good faith to provide emergency care in the event of an overdose, and NALs increase the distribution and accessibility of Naloxone. Research suggests that increasing naloxone access will be the second most effective intervention for reducing overdoses. Most states have the following three or varying degrees of Naloxone access: third party distribution, pharmacist prescribing power, and standing orders. The standing order for naloxone allows for its distribution to a patient if they meet a certain criterion, which is most often the prescription of an opioid. The effectiveness of this legislation has been disputed since its success depends on the change in behavior of people who are present during an overdose and the accessibility of naloxone. In 2001, New Mexico was the first state to create a NAL, which granted third-party prescribing and criminal immunity to prescribers. By 2017, all states had a NAL in place. Connecticut first implemented a GSL in 2011, and it has been updated yearly since 2014. Some research suggests that Connecticut's GSL has not affected overdose deaths but has resulted in positive behavioral changes with an increase of 9 calls; however, deaths may still continue to increase in spite of the increased awareness from GSLs. From 2000 to 2014, McClellan et al.
=== Protein === MIA3 is a member of the MIA/OTOR family. The full-length protein spans 1,907 amino acids and localizes to the ER exit sites. It contains an N-terminal, SH3-like domain, two predicted transmembrane domains, a coiled-coiled domain, and a C-terminal, proline-rich domain. The SH3-like domain faces the ER lumen, where it can bind cargo for COPII carrier biogenesis, while the proline-rich domain faces the cytoplasm, where it can bind the COPII components Sec23/24. Of the two predicted transmembrane domains, only one actually crosses the membrane, whereas the second likely forms a hairpin structure that is only embedded in but not crossing the membrane.
Sources: en.wikipedia.org
=== Symbiosis === Symbionts are the primary providers of nutrition for Osedax. However, these symbionts also possess genes, secretion systems, and toxins that disrupt the Osedax membrane and facilitate recurrent infections of adult Osedax through the root tips. There is ongoing debate in the literature over whether the symbiosis in Osedax roots is commensal or mutualistic. The symbiotic relationship between Osedax and its accompanying bacteria may be transferred either via vertical or horizontal transmission. Osedax species use collagen, which is the primary organic component in bone. Collagen is degraded using a family of endopeptidases called matrix metalloproteinases (MMPs), which facilitates nutrient absorption by the Osedax. The roots of the Osedax express high amounts of V-ATPase and carbonic anhydrase enzymes, which allows the Osedax to dissolve and absorb collagen and lipids. Once dissolved, the nutrients are either used by the Osedax, or transported to the symbionts for further catabolism. As the endosymbionts lack secreted M9 peptidase, they rely on the Osedax worm to source extracellular collagen. The symbionts in the Oceanospirillales order have then been observed to further process the collagen using collagenolytic enzymes. Sequencing of the Osedax worm genome has suggested an evolved dependency on its endosymbionts. This is revealed by genomic streamlining, where increased functional groups were observed despite the loss of some gene families. Six incomplete pathways were discovered in the Osedax worm genome which were supplemented by the endosymbionts.
Vitamin B12, also known as cobalamin or extrinsic factor, is a water-soluble vitamin involved in metabolism. One of eight B vitamins, it serves as a vital cofactor in DNA synthesis and both fatty acid and amino acid metabolism. It plays an essential role in the nervous system by supporting myelin synthesis and is critical for the maturation of red blood cells in the bone marrow. Animals require B12 but plants do not, relying instead on alternative enzymatic pathways. Vitamin B12 is the most chemically complex of all vitamins, and is synthesized exclusively by certain archaea and bacteria. Natural food sources include meat, shellfish, liver, fish, poultry, eggs, and dairy products. It is also added to many breakfast cereals through food fortification and is available in dietary supplement and pharmaceutical forms. Supplements are commonly taken orally but may be administered via intramuscular injection to treat deficiencies. In healthy adults, vitamin B12 deficiency is not common, mainly because body stores of the vitamin are substantial and turnover is slow, with relatively low dietary requirements. However, B12 deficiency in the elderly is a significant concern, and is related to dementia. The most common cause in developed countries is impaired absorption due to loss of gastric intrinsic factor (IF), required for absorption. A related cause is reduced stomach acid production with age or from long-term use of proton-pump inhibitors, H2 blockers, or other antacids, and interaction with metformin.
== Signs and symptoms == The typical signs of malignant hyperthermia are due to a hypercatabolic state, which presents as a very high temperature, an increased heart rate and abnormally rapid breathing, increased carbon dioxide production, increased oxygen consumption, mixed acidosis, rigid muscles, and rhabdomyolysis. These signs can develop any time during the administration of the anesthetic triggering agents. Rarely, signs may develop up to 40 minutes after the end of anaesthesia.
Sources: en.wikipedia.org
=== Adolescence and prodrome === The onset of BPD symptoms typically occurs during adolescence or early adulthood, with possible early signs in childhood. Predictive symptoms in adolescents include body image issues, extreme sensitivity to rejection, behavioral challenges, non-suicidal self-injury, seeking exclusive relationships, and profound shame. Although many adolescents exhibit these symptoms without developing BPD, those who do are significantly more likely to develop the disorder and potentially face long-term social challenges. BPD is recognized as a stable and valid diagnosis during adolescence, supported by the DSM-5 and ICD-11. Early detection and treatment of BPD in young individuals are emphasized in national guidelines across various countries, including the US, Australia, the UK, Spain, and Switzerland, highlighting the importance of early intervention. Historically, diagnosing BPD during adolescence was met with caution, due to concerns about the accuracy of diagnosing young individuals, the potential misinterpretation of normal adolescent behaviors, stigma, and the stability of personality during this developmental stage. Even so, research has confirmed the validity and clinical utility of the BPD diagnosis in adolescents, though misconceptions persist among mental health care professionals, contributing to clinical reluctance in diagnosing and a key barrier to the provision of effective treatment of BPD in this population.
By May 1619, the San Juan Bautista was in the Port of Luanda loading 350 African slaves for transport. The captain, a relative of de Acuña, sailed the Africans to Jamaica, during which time over one hundred of them died of illness. He traded twenty-four of them and set sail for Veracruz, but was attacked by two English ships, the White Lion and Treasurer. The captain surrendered, and the English ships split sixty of the Africans between them. The incident was described as follows:
A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 (68Ga), copper-64 (64Cu), and fluorine-18 (18F) is carried out with a positron emission tomography (PET) scanner. For gamma emitters such as technetium-99m (99mTc) and indium-111 (111In) single-photon emission computed tomography (SPECT) imaging is performed with a gamma camera. As well as the diagnosis and staging of prostate cancer, PSMA imaging can also be used to assess suitability for and plan treatment with external beam radiotherapy and PSMA-targeted radionuclide therapy.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.